Prediction of Nonremission to Antidepressant Therapy Using Diffusion Tensor Imaging
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Over 50% of outpatients with nonpsychotic major depressive disorder (MDD) do not achieve remission with any single antidepressant medication (ADM). There are currently no clinically useful pretreatment measures that inform the decision to prescribe or select ADMs. This report examines whether a biomarker based on diffusion tensor imaging (DTI) measures of brain connectivity can identify a subset of nonremitting patients with a sufficiently high degree of specificity that use of a medication that is likely to fail could be avoided. METHODS: MDD outpatients recruited from community and primary-care settings underwent pretreatment magnetic resonance imaging as part of the international Study to Predict Optimized Treatment in Depression (conducted December 2008-June 2014). DSM-IV criteria and a 17-item Hamilton Depression Rating Scale (HDRS17) score ≥ 16 confirmed the primary diagnosis of nonpsychotic MDD. Data from the first cohort of MDD patients (n = 74) were used to calculate fractional anisotropy measures of the stria terminalis and cingulate portion of the cingulate bundle (CgC). On the basis of our previous data, we hypothesized that nonremission might be predicted using a ratio of these 2 values. Remission was defined as an HDRS17 score of ≤ 7 following 8 weeks of open-label treatment with escitalopram, sertraline, or venlafaxine extended-release, randomized across participants. The second study cohort (n = 83) was used for replication. RESULTS: Thirty-four percent of all participants achieved remission. A value > 1.0 for the ratio of the fractional anisotropy of the stria terminalis over the CgC identified 38% of the nonremitting participants with an accuracy of 88% (test cohort; odds ratio [OR] = 9.6; 95% CI, 2.0-45.9); 24% with an accuracy of 83% (replication cohort; OR = 1.8; 95% CI, 0.5-6.9) and 29% with an accuracy of 86% (pooled data; OR = 4.0; 95% CI, 1.5-11.1). Treatment moderation analysis showed greater specificity for escitalopram and sertraline (χ(2) = 8.07; P = .003). CONCLUSIONS: To our knowledge, this simple DTI-derived metric represents the first brain biomarker to reliably identify nonremitting patients in MDD. The test identifies a meaningful proportion of nonremitters, has high specificity, and may assist in managing the antidepressant treatment of depression. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00693849.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Difficult-to-treat depression: A clinical and research roadmap for when remission is elusive
Rush, A. J., Aaronson, S. T., & Demyttenaere, K. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418808585 · Cited by 120
“Can we identify patients with DTD earlier in the course of their illness? Researchers have attempted to recognize these individuals prior to treatment initiation (Grieve et al., 2016; Perlis, 2011; Uher et al., 2010) because early detection of patients with DTD might expedite consideration of alternative therapies, a…”
BackgroundSelf-citationMaller, J. J., Broadhouse, K., Rush, A. J., Gordon, E., Koslow, S., & Grieve, S. M. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.224 · Cited by 87
Self-citationMRI predictors of pharmacotherapy response in major depressive disorder
Gerlach, A. R., Karim, H. T., Peciña, M., Ajilore, O., Taylor, W. D., Butters, M. A., & Andreescu, C. (2022) · NeuroImage: Clinical · doi:10.1016/j.nicl.2022.103157 · Cited by 57
Metadata
- Authors
- Grieve, S. M., Korgaonkar, M. S., Gordon, E., Williams, L. M., & Rush, A. J.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2016-04-27
- Volume
- 77
- Issue
- 04
- Pages
- e436-e443
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2343147474
- Cited by
- 37
- References
- 0
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.